Neoplasms

Symptoms and General Pathology

All Conditions

Substance Related Disorders

Skin and Connective Tissue Diseases

Rare Diseases

Neoplasm Metastasis

Osteosarcoma

Drug-Related Side Effects and Adverse Reactions

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Sarcoma

Chemically-Induced Disorders

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Etoposide

Apatinib

Ifosfamide

Etoposide phosphate

Isophosphamide mustard

Mechlorethamine

Enzyme Inhibitors

Protein Kinase Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3

Apatinib Mesylate

ifosfamide and etoposide

Today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic polychemotherapy followed by local surgical therapy and then postoperative (adjuvant) chemotherapy, long-term, disease-free survival can be achieved in 60- 70% of osteosarcoma patients. However treatment options for osteosarcomas, especially in the setting of metastatic or unresectable disease, are very scarce. Apatinib has been proved to be an effective agent to prolong progression-free survival in advanced osteosarcoma. But after 4-6 months' treatment, secondary resistance always occurred with musculoskeletal lesions' progression or new metastasis.

Nowadays giving therapeutic doses of IE concurrently with anti-angiogenesis tyrosine kinase inhibitors is a conceptually attractive strategy for treating patients with refractory osteosarcoma according to prospective trial of lenvatinib +IE reported by Gaspar et al at 2019 ESMO and 2020 ESMO. Thus This study was designed to review our experience in real world for off-label use and characterize the toxicity profile of concurrent apatinib+IE and IE alone in patients with relapsed or refractory osteosarcoma.

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China

from start treatment to progression/death

Peking University Shougang Hospital

Peking University People's Hospital

Carcinoma

Cholangiocarcinoma

Carcinoma, Transitional Cell

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Transitional Cell Carcinoma

Bile Duct Cancer

Intrahepatic Cholangiocarcinoma

Dose escalation of KIN-3248 in patients with solid tumors

Dose expansion evaluating the recommended dose and schedule of KIN-3248 identified from Part A

KIN-3248 will be administered orally once daily in 28-day cycles

KIN-3248

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

This is a two-part, open label, multi-center, dose escalation and dose expansion study in participants with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

Part A (dose escalation) is aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of KIN-3248, and determining the maximum tolerated dose (MTD) of daily dosing of KIN-3248.

Part B (dose expansion) may open once either the MTD and/or a biologically active dose of KIN-3248 is identified. Part B is aimed at evaluating the safety and efficacy of KIN-3248 at the recommended dose and schedule in participants with cancers harboring FGFR2 and/or FGFR3 gene alterations, including intrahepatic cholangiocarcinoma (ICC), urothelial cancer (UC), and other solid tumors.

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

Kinnate Biopharma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma	NCT04690231	Effect of Drug Toxicity, Drug Secondary Resis...	Apatinib Mesyla... ifosfamide and ...	3 Years -	Peking University People's Hospital
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	NCT05242822	Solid Tumor, Ad... Intrahepatic Ch... Urothelial Carc...	KIN-3248	18 Years -	Kinnate Biopharma
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	NCT05242822	Solid Tumor, Ad... Intrahepatic Ch... Urothelial Carc...	KIN-3248	18 Years -	Kinnate Biopharma
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations	NCT05242822	Solid Tumor, Ad... Intrahepatic Ch... Urothelial Carc...	KIN-3248	18 Years -	Kinnate Biopharma

Spots Global Cancer Trial Database for secondary resistance